Merck, Inc.
🇺🇸United States
A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT02549027
Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
Phase 2
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: V114-BBiological: Prevnar 13®Biological: V114-A
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 690
- Registration Number
- NCT02547649
A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT02532868
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 614
- Registration Number
- NCT02532855
A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
Phase 1
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: V114 High DoseBiological: V114 Medium Dose with Alternative Carrier ProteinBiological: V114 Medium DoseBiological: V114 High Dose with Alternative Carrier ProteinBiological: Prevnar 13™
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 338
- Registration Number
- NCT02531373
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
Phase 3
Terminated
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: 5-HT3 antagonist
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT02519842
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: ZOSTAVAX™Biological: Placebo to ZOSTAVAX™Biological: Influenza Vaccine
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 882
- Registration Number
- NCT02519855
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Phase 3
Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: PembrolizumabOther: Placebo
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1177
- Registration Number
- NCT02504372
Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
Phase 3
Completed
- Conditions
- Prevention of Ebola Infection
- Interventions
- Biological: V920 Consistency Lot BBiological: V920 Consistency Lot ABiological: V920 High-dose LotBiological: V920 Consistency Lot CBiological: Placebo to V920
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1197
- Registration Number
- NCT02503202
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Phase 3
Completed
- Conditions
- Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 763
- Registration Number
- NCT02494583
© Copyright 2025. All Rights Reserved by MedPath